Ansseau M, von Frenckell R, Cerfontaine J L, Papart P, Franck G, Timsit-Berthier M, Geenen V, Legros J J
Biological Psychiatry and Psychopharmacology Unit, Centre Hospitalier Universitaire (B 33), Liège Sart Tilman, Belgium.
Psychiatry Res. 1987 Nov;22(3):193-206. doi: 10.1016/0165-1781(87)90034-5.
Several lines of evidence suggest catecholamine overactivity (noradrenergic and/or dopaminergic) in mania. We studied the growth hormone (GH) response to clonidine (an alpha-adrenergic agonist) and apomorphine (a dopaminergic agonist) in seven inpatients meeting Research Diagnostic Criteria for mania. They had been completely drug free for at least 3 months before the neuroendocrine procedures and were age- and sex-matched to seven major depressive and seven minor depressive inpatients, drug free for at least 2 weeks. GH was assayed every 20 min for 40 min before and 120 min after either clonidine (0.15 mg i.v.) or apomorphine (0.5 mg s.c.), with an interval of at least 2 days between the tests. The three groups differed significantly in the GH peak response: after clonidine (mean +/- SD), 3.2 +/- 2.4 ng/ml in manics, 3.2 +/- 2.4 ng/ml in major depressives, and 13.2 +/- 8.7 ng/ml in minor depressives; after apomorphine, 10.5 +/- 7.4, 3.2 +/- 1.9, and 26.9 +/- 15.8, respectively. While there were significant differences between manics and minor depressives and between major and minor depressives after both clonidine and apomorphine, manics did not significantly differ from major depressives on either test. These results do not provide neuroendocrine support to the catecholaminergic hypothesis of manic disorders.
多项证据表明躁狂症患者存在儿茶酚胺活性过高（去甲肾上腺素能和/或多巴胺能）的情况。我们研究了7名符合躁狂症研究诊断标准的住院患者对可乐定（一种α-肾上腺素能激动剂）和阿扑吗啡（一种多巴胺能激动剂）的生长激素（GH）反应。在进行神经内分泌检查之前，他们已完全停药至少3个月，并且在年龄和性别上与7名重度抑郁症患者和7名轻度抑郁症患者相匹配，后者也已停药至少2周。在静脉注射可乐定（0.15mg）或皮下注射阿扑吗啡（0.5mg）之前40分钟和之后120分钟，每隔20分钟检测一次GH，两次检测之间间隔至少2天。三组患者的GH峰值反应存在显著差异：注射可乐定后（平均值±标准差），躁狂症患者为3.2±2.4ng/ml，重度抑郁症患者为3.2±2.4ng/ml，轻度抑郁症患者为13.2±8.7ng/ml；注射阿扑吗啡后，分别为10.5±7.4、3.2±1.9和26.9±15.8。虽然在注射可乐定和阿扑吗啡后，躁狂症患者与轻度抑郁症患者之间以及重度抑郁症患者与轻度抑郁症患者之间存在显著差异，但在两项测试中，躁狂症患者与重度抑郁症患者之间没有显著差异。这些结果并未为躁狂症的儿茶酚胺能假说提供神经内分泌学支持。
